Human epidermal growth factor receptor 2 (HER2), also known as ErbB-2, cluster of differentiation 340 (CD340), proto-oncogene Neu, is encoded by the ERBB2 gene. As a member of the human epidermal growth factor receptor (HER/EGFR/ERBB) family, HER2 has become an important biomarker and target of therapy for breast cancer. Not only the overexpression of HER2 occurs in breast cancer, but also it is strongly associated with the ovarian cancer, stomach cancer, lung adenocarcinoma, uterine cancer, salivary gland cancer, acute lymphoblastic leukemia (ALL), bladder cancer, childhood medulloblastoma, colorectal cancer, oral squamous cell carcinoma, germ-cell testicular tumor, cholangiocarcinoma, osteosarcoma, pancreatic adenocarcinoma and prostate cancer.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy product with the complete TCR complex without HLA matching dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE